pSG2.HIVconsv(University of Oxford)(pSG2.HIVconsv(University of Oxford)) - 在研适应症：HIV感染_专利_临床

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

Ichor Medical Systems, Inc.

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 pSG2.HIVconsv(University of Oxford) 相关的临床试验

NCT02099994

/ Completed临床1/2期IIT

A Phase I/IIa Clinical Trial of HIV-1 Vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in Combined Regimens in Healthy HIV-1/2-negative Adults in Nairobi.

The study is part of a long-term aim to develop an effective HIV-1 vaccine and will evaluate safety and immunogenicity of vaccines focusing T cell responses on the conserved region of the HIV-1 proteome. The vaccines used are pSG2.HIVconsv DNA (D), MVA.HIVconsv (M) and Ad35-GRIN (A), delivered in regimens AM, DDDAM and DeDeDeAM, where e indicates electroporation.

开始日期2014-03-01

申办/合作机构

University of Oxford

[+4]

NCT02425241

/ Completed临床1/2期IIT

A Randomised Double-blind, Placebo-controlled Phase I/IIa Trial to Investigate the Effect of Depletion of Serum Amyloid P Component (SAP) on the Immune Response to DNA Vaccination in Healthy Male Volunteers

This is a clinical proof-of-concept (PoC) study of DNA vaccination after SAP depletion. The investigators will measure the immune responses to DNA vaccination against HIV-1 in healthy adult male volunteers, comparing a group in whom SAP has been completely depleted at the time of DNA vaccination and a control group vaccinated without SAP depletion.

开始日期2013-10-01

申办/合作机构

University College London

[+3]

100 项与 pSG2.HIVconsv(University of Oxford) 相关的临床结果

登录后查看更多信息

100 项与 pSG2.HIVconsv(University of Oxford) 相关的转化医学

登录后查看更多信息

100 项与 pSG2.HIVconsv(University of Oxford) 相关的专利（医药）

登录后查看更多信息

100 项与 pSG2.HIVconsv(University of Oxford) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
获得性免疫缺陷综合征	临床2期	肯尼亚	Ichor Medical Systems, Inc.	2014-03-01
HIV感染	临床1期	赞比亚	University of Oxford	2022-01-30
HIV感染	临床1期	乌干达	University of Oxford	2022-01-30
HIV感染	临床1期	肯尼亚	University of Oxford	2022-01-30